Phase 1Recruiting
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
A Multi-center, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of HJB647 in Participants With Chronic Stable Heart Failure With Reduced Ejection Fraction
- Sponsor
- Novartis Pharmaceuticals (Industry)
- Enrolment
- 12 planned
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- HJB647 low dose; HJB647 high dose; Placebo
- Ages
- adults, older adults
- Registry
- NCT07465653
From the registry
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
Primary outcomes
- Number of participants with Adverse Events (AEs)
- Number of participants with clinically significant changes in vital signs